Biohaven Ltd. (BHVN) SVP awarded 175,000 stock options with 4-year vesting

Rhea-AI Filing Summary

Gentile Kimberly reported acquisition or exercise transactions in this Form 4 filing.

Biohaven Ltd. reported that senior vice president of clinical operations Kimberly Gentile received a grant of stock options covering 175,000 shares. The options were awarded on February 27, 2026 and will vest in four equal installments on February 27 of 2026, 2027, 2028 and 2029, conditioned on her continuous service with the company.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gentile Kimberly

(Last) (First) (Middle)

C/O BIOHAVEN LTD.

215 CHURCH STREET

(Street)

NEW HAVEN CT 06510

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Biohaven Ltd. [ BHVN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Clinical Operations

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to buy)	$11.52	02/27/2026		A		175,000		(1)	02/27/2036	Common Shares	175,000	$0	175,000	D

Explanation of Responses:

1. The shares underlying this option vest in four equal installments on February 27, 2026, 2027, 2028 and 2029, subject to the Reporting Person's continuous service with the Issuer at each vesting date.

Remarks:

	/s/ George Clark, Attorney-in-Fact	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Biohaven Ltd. (BHVN) report for Kimberly Gentile?

Biohaven Ltd. reported that Kimberly Gentile received a grant of stock options covering 175,000 shares. The award was recorded on February 27, 2026 and reflects a direct ownership position following the transaction.

How many Biohaven (BHVN) stock options were granted to Kimberly Gentile?

Kimberly Gentile was granted stock options representing 175,000 shares of Biohaven Ltd. stock. After this grant, the total number of derivative securities she held related to this award was 175,000, according to the Form 4 data.

What is the vesting schedule for Kimberly Gentile’s Biohaven (BHVN) stock options?

The options vest in four equal installments on February 27, 2026, 2027, 2028 and 2029. Each installment is subject to Kimberly Gentile’s continuous service with Biohaven Ltd. on the applicable vesting date, as disclosed in the footnote.

What type of transaction is reported in this Biohaven (BHVN) Form 4?

The Form 4 shows a grant or award acquisition of derivative securities, specifically stock options. The transaction code is “A,” and the transaction_direction field classifies it as an acquisition rather than a sale or disposition.

Is Kimberly Gentile’s Biohaven (BHVN) option grant a direct or indirect holding?

The option grant is reported as a direct holding for Kimberly Gentile. The Form 4 lists the ownership type and code as direct, with no separate entity or indirect ownership structure noted.

On what date was Kimberly Gentile’s Biohaven (BHVN) option grant effective?

The grant of stock options to Kimberly Gentile was effective on February 27, 2026. This date is reported as the transaction date for the award in the Form 4 insider filing data.